Impact of Molecular Pathology on Classifying Diffuse Gliomas
Impact of Molecular Pathology on Classifying Diffuse Gliomas
About 30% of WHO low-grade adult diffuse astrocytomas and fewer than 10% of morphologically diagnosed OD are IDH-wt; by contrast, the majority of newly encountered GBM is IDH-wt. Among the IDH-wt low-grade astrocytoma group, some of these cases harbor chromosomal and molecular alterations, thus aligning them with de novo GBM. The remaining cases possess a variety of genetic and biochemical alterations, some of which are more akin to pediatric gliomas, particularly BRAF alterations and histone modifications, facilitating further subclassification.
Diffuse IDH-wt Gliomas in Adults
About 30% of WHO low-grade adult diffuse astrocytomas and fewer than 10% of morphologically diagnosed OD are IDH-wt; by contrast, the majority of newly encountered GBM is IDH-wt. Among the IDH-wt low-grade astrocytoma group, some of these cases harbor chromosomal and molecular alterations, thus aligning them with de novo GBM. The remaining cases possess a variety of genetic and biochemical alterations, some of which are more akin to pediatric gliomas, particularly BRAF alterations and histone modifications, facilitating further subclassification.
Source...